Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease.

BACKGROUND Patients with stroke or transient ischemic attack are at high risk of another stroke, and there is need for improved strategies to predict recurrent stroke. OBJECTIVE To assess the prognostic value of levels of soluble vascular cell adhesion molecule 1 (sVCAM-1), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein, homocysteine, renin, and lipids and lipoprotein particle concentration and size in patients with previous stroke or transient ischemic attack. DESIGN, SETTING, AND PARTICIPANTS A nested case-control study of participants of the Perindopril Protection Against Recurrent Stroke Study was performed. The Perindopril Protection Against Recurrent Stroke Study was a placebo-controlled trial of a perindopril erbumine-based, blood pressure-lowering regimen that reduced ischemic stroke risk by 24% among individuals with previous stroke or transient ischemic attack. Each of 252 patients who experienced ischemic stroke during a mean follow-up of 3.9 years was matched to 1 to 3 control patients. Matching variables were age, sex, treatment allocated, region, and most recent qualifying event at randomization. MAIN OUTCOME MEASURES Risk of ischemic stroke predicted by baseline levels of sVCAM-1, NT-proBNP, C-reactive protein, homocysteine, renin, and lipids and lipoprotein particle concentration and size. RESULTS Levels of sVCAM-1 and NT-proBNP predicted recurrent ischemic stroke. The odds ratio for patients in the highest, as compared with the lowest, quarter was 2.24 (95% confidence interval, 1.35-3.73) for sVCAM-1 level and 1.62 (95% confidence interval, 0.98-2.69) for NT-proBNP level, after adjustment for matching and other risk factors. Patients in the highest quarters for both sVCAM-1 and NT-proBNP levels had 3.6 times the risk of recurrent ischemic stroke compared with patients in the lowest quarters for both biologic markers. Level of sVCAM-1 was similarly predictive of ischemic stroke in patients allocated to placebo and perindopril-based therapy. Baseline plasma levels of C-reactive protein, homocysteine, renin, and lipids and lipoprotein particle concentration and size did not predict recurrent ischemic stroke risk. CONCLUSION Measurement of sVCAM-1 and NT-proBNP levels provides prognostic information for recurrent ischemic stroke beyond traditional risk factors.

[1]  Simon Davies,et al.  Epidemiology: Study Design and Data Analysis (2nd ed.) , 2006 .

[2]  M. Woodward,et al.  Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke , 2005, Stroke.

[3]  M. Woodward,et al.  Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease , 2005, Circulation.

[4]  P. Hildebrandt,et al.  N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. , 2005, JAMA.

[5]  P. Hildebrandt,et al.  N-Terminal Pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictors of Mortality and Cardiovascular Events in Older Adults , 2005 .

[6]  M. Woodward,et al.  Prediction of Heart Failure by Amino Terminal-pro–B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease , 2005, Hypertension.

[7]  B. Psaty,et al.  Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups , 2004, Neurology.

[8]  M. Woodward,et al.  Serum Triglycerides as a Risk Factor for Cardiovascular Diseases in the Asia-Pacific Region , 2004, Circulation.

[9]  M. Tremblay,et al.  Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.D300041-JLR200 , 2004, Journal of Lipid Research.

[10]  K. Yano,et al.  High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu heart program. , 2004, American journal of epidemiology.

[11]  D. Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .

[12]  C. Anderson,et al.  Ten-Year Risk of First Recurrent Stroke and Disability After First-Ever Stroke in the Perth Community Stroke Study , 2004, Stroke.

[13]  L. Chambless,et al.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.

[14]  M. Woodward,et al.  Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History: The PROGRESS Trial , 2003, Stroke.

[15]  J. Michael Gaziano,et al.  Cholesterol and the Risk of Ischemic Stroke , 2003, Stroke.

[16]  Progress.  Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease A Randomized Controlled Trial , 2003 .

[17]  M. Woodward,et al.  Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease: A Randomized Controlled Trial , 2003, Stroke.

[18]  À. Rovira,et al.  C-Reactive Protein Predicts Further Ischemic Events in First-Ever Transient Ischemic Attack or Stroke Patients With Intracranial Large-Artery Occlusive Disease , 2003, Stroke.

[19]  Mark Woodward,et al.  Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. , 2003, International journal of epidemiology.

[20]  T. Truelsen,et al.  Homocysteine and Risk of Recurrent Stroke , 2003, Stroke.

[21]  K. Yano,et al.  C-Reactive Protein and the Future Risk of Thromboembolic Stroke in Healthy Men , 2003, Circulation.

[22]  A. Hofman,et al.  Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study , 2003, Journal of neurology, neurosurgery, and psychiatry.

[23]  P. Ridker,et al.  Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women , 2002, Circulation.

[24]  P. Ridker,et al.  Inflammatory bio‐markers and cardiovascular risk prediction , 2002, Journal of internal medicine.

[25]  Konrad Jamrozik,et al.  Long-Term Disability After First-Ever Stroke and Related Prognostic Factors in the Perth Community Stroke Study, 1989–1990 , 2002, Stroke.

[26]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[27]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[28]  G. Hankey,et al.  Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations* , 1999, The Lancet.

[29]  R W Alexander,et al.  Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. , 1999, Circulation.

[30]  Mark Woodward,et al.  Epidemiology: Study Design and Data Analysis , 1999 .

[31]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[32]  R. Crooks,et al.  Assay of plasma homocysteine: light sensitivity of the fluorescent 7-benzo-2-oxa-1, 3-diazole-4-sulfonic acid derivative, and use of appropriate calibrators. , 1996, Clinical chemistry.

[33]  J. Ubbink,et al.  Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. , 1991, Journal of chromatography.